Here are 1-3 brief analogies for Trevi Therapeutics (TRVI):

• An early-stage Vertex Pharmaceuticals, but focused on developing a single drug for chronic itching and cough.
• A biotech much like a young Regeneron, betting on one drug (Haduvio) to treat chronic itching and cough.

• Haduvio: An oral extended-release formulation of nalbuphine currently in clinical trials for treating chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis.

Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on the development of Haduvio. As the company's lead product, Haduvio, is currently in Phase IIb/III clinical trials, it has not yet received regulatory approval for commercialization.

Consequently, Trevi Therapeutics does not currently have major customers, either other companies or categories of individuals, for its product. Its primary activities are centered around research and development, and the advancement of its clinical trials.

• Siegfried AG (SFZN)
• Catalent Pharma Solutions, Inc. (CTLT)

Jennifer Good, Co-Founder, President and CEO

Jennifer Good co-founded Trevi Therapeutics in 2011. Prior to founding Trevi, Ms. Good served in various roles at Penwest Pharmaceuticals Co. from 1997 to 2010, including President and Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer. She successfully transitioned Penwest from a development-stage company to one generating over $50 million in annual revenues. Penwest Pharmaceuticals was acquired by Endo Pharmaceuticals in the fourth quarter of 2010 for approximately $168 million, with Ms. Good leading the negotiations for this acquisition. She previously served on the board of Juniper Pharmaceuticals until its acquisition by Catalent, Inc. in 2018. Ms. Good currently serves on the board of Rhythm Pharmaceuticals.

David Hastings, Chief Financial Officer

David Hastings assumed the role of Chief Financial Officer of Trevi Therapeutics effective January 6, 2026. He brings over 25 years of financial leadership in public life sciences and biopharmaceutical companies. Most recently, he served as CFO of Arbutus Biopharma Corporation from June 2018 until March 2025. His previous roles include Senior Vice President and CFO of Unilife Corporation from 2015 to 2017, and CFO and Executive Vice President at Incyte Corporation from 2003 to 2014, where he oversaw the financial aspects of the company's transition from research and development to commercialization. Mr. Hastings also served as Vice President, CFO, and Treasurer at ArQule Inc. During his tenure at ArQule, he played a significant role in the company's transition into a drug discovery and development organization and in two strategic acquisitions. He has raised over $2 billion in equity and debt financing throughout his career.

Thomas Sciascia, M.D., Co-Founder, Chief Scientific Officer

Dr. Thomas Sciascia co-founded Trevi Therapeutics in March 2011. Prior to Trevi, he was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest Pharmaceuticals. His career also includes time as a consultant at Quintiles, Inc. and as Medical Director at Transkaryotic Therapies, Inc., which was later acquired by Shire Pharmaceuticals Group plc. He is a board-certified neurologist.

James Cassella, Ph.D., Chief Development Officer

Dr. James Cassella was appointed Chief Development Officer of Trevi Therapeutics in September 2024. He previously served as Chief Development Officer for Concert Pharmaceuticals, Inc. from February 2015, where he led development activities that resulted in the successful FDA approval of the autoimmune JAK inhibitor, Leqselvi™. Dr. Cassella was a key member of the executive team and the corporate transaction team that led to Concert Pharmaceuticals' $576 million acquisition by Sun Pharmaceutical Industries in 2023. Before joining Concert, he was Executive Vice President, Research and Development and Chief Scientific Officer at Alexza Pharmaceuticals from 2004-2015. He has over 35 years of experience in CNS drug development.

Farrell Simon, Pharm.D., Chief Commercial Officer

Farrell Simon serves as the Chief Commercial Officer for Trevi Therapeutics. He is an experienced general manager with a background in leading operating plans for brands across various sizes and product lifecycles. Prior to joining Trevi, Mr. Simon spent 10 years at Pfizer in commercial and operations roles, including serving as Chief of Staff to the Group President of Biopharma. He also gained general management, marketing, and medical affairs experience at Procter & Gamble. Mr. Simon is the founder and CEO of The Simon Cancer Foundation.

Key Risks to Trevi Therapeutics (TRVI)

• Clinical Trial and Regulatory Approval Risk for Haduvio: Trevi Therapeutics is a clinical-stage biopharmaceutical company heavily reliant on the successful development and commercialization of its lead product candidate, Haduvio. Haduvio is currently in Phase IIb/III clinical trials for chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. The success, cost, and timing of these clinical trials are uncertain. There is a risk that Haduvio may not demonstrate the desired safety and efficacy in ongoing or future clinical trials, or that positive data from earlier trials may not predict success in later trials. Even with successful clinical data, there is no guarantee of obtaining regulatory approvals from authorities like the FDA. The company recently secured FDA alignment for two parallel Phase 3 trials for Haduvio in IPF-related chronic cough, with initiation targeted for Q2 and H2 2026, respectively. Failure to achieve positive results or regulatory approval would significantly harm the company's business prospects.
• Dependence on a Single Product Candidate and Funding Needs: Trevi Therapeutics' business is substantially dependent on the successful development and eventual commercialization of Haduvio. The company currently has no revenue and is operating at a loss, making it a single-asset story with significant funding needs. The decision to run two parallel Phase 3 trials, even though the FDA indicated one could be sufficient, likely increases the company's cash needs and execution risk. Any setbacks in the Haduvio program could have a severe impact on the company's financial health and future viability.
• Opioid-Related Labeling and Market Acceptance Risks: Haduvio is an oral extended-release formulation of nalbuphine, which is a kappa agonist/mu antagonist (KAMA) and an opioid. Despite indications of low abuse potential, there is a possibility that the FDA could classify Haduvio as a "controlled substance" due to its opioid class. Such a labeling could constrain its distribution and affect commercial potential. Furthermore, the long-term efficacy, safety, and tolerability of Haduvio, especially as an opioid-based chronic cough medicine, are paramount for market acceptance and commercial success. The competitive landscape for chronic cough, particularly in refractory chronic cough (RCC), also presents a risk, with other pharmaceutical giants evaluating competing treatments.

Addressable Markets for Trevi Therapeutics' Main Products or Services

Trevi Therapeutics (symbol: TRVI) is developing Haduvio (nalbuphine ER) for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis (IPF).

Chronic Pruritus

The addressable market for chronic pruritus across the seven major markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately USD 3,845 million in 2025. This market is projected to expand significantly, reaching an estimated USD 8,110 million by 2034, demonstrating a robust Compound Annual Growth Rate (CAGR) of 8.6%. The United States is expected to be the primary contributor to this market. Globally, the chronic pruritus therapeutics market was valued at USD 8.2 billion in 2021 and is anticipated to reach USD 12.1 billion by 2030, growing at a CAGR of 4.4% from 2022 to 2030. In 2024, the global pruritus therapeutics market was estimated at USD 9.6 billion and is projected to reach USD 14.4 billion by 2034. Specifically for the U.S., the pruritus therapeutics market accounted for USD 3.9 billion in revenues in 2024 and is forecasted to reach USD 5.8 billion by 2034.

Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) and Refractory Chronic Cough (RCC)

The addressable market for chronic cough in idiopathic pulmonary fibrosis (IPF) across the 7MM was approximately USD 154 million in 2022. The United States held the largest share of this market in 2022, accounting for nearly 61%. This market is projected for substantial growth during the forecast period. In addition, there are an estimated 2 million to 3 million patients in the U.S. suffering from refractory chronic cough (RCC), a condition for which there are currently no FDA-approved therapies.

Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company, currently reports no revenue. Its future revenue growth over the next 2-3 years is primarily dependent on the successful clinical development and potential commercialization of its lead investigational therapy, Haduvio (oral nalbuphine ER), for various neurologically mediated conditions. Analysts forecast Trevi Therapeutics' revenue to remain at $0 for 2026 and 2027, with significant revenue generation projected to begin in 2028, averaging approximately $8.46 billion.

The key expected drivers of future revenue growth for Trevi Therapeutics are:

1. Successful Clinical Development and Regulatory Approval of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

   Trevi Therapeutics has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for Haduvio in IPF-related chronic cough, aligning on the Phase 3 clinical program. The company plans to initiate two pivotal Phase 3 trials concurrently, with the first scheduled to launch in the second quarter of 2026 and the second in the latter half of 2026. This represents a substantial market opportunity, as approximately 150,000 IPF patients in the United States suffer from chronic cough, and there are currently no FDA-approved therapies for this condition.

2. Expansion of Haduvio into the Refractory Chronic Cough (RCC) Market

   Trevi Therapeutics is advancing Haduvio into a Phase 2b trial for refractory chronic cough (RCC), which is expected to begin in the first half of 2026. This indication also represents a significant unmet medical need, with an estimated 2 to 3 million U.S. patients suffering from RCC, for which there are no FDA-approved therapies. Haduvio has demonstrated statistically significant efficacy in previous Phase 2a trials for RCC.

3. Market Expansion into Non-IPF Interstitial Lung Disease (non-IPF ILD) Chronic Cough

   The company plans to initiate a Phase 2 trial for chronic cough in patients with non-IPF interstitial lung disease (non-IPF ILD) in 2026. This market opportunity is considered to be potentially as large as that for IPF chronic cough, with approximately 228,000 U.S. patients having non-IPF ILD, and 50-60% of them experiencing uncontrolled chronic cough. This expansion would broaden the potential patient population for Haduvio considerably.

Share Issuance

Inbound Investments

Capital Expenditures